Skip to main content
Top
Published in: Langenbeck's Archives of Surgery 1/2023

Open Access 01-12-2023 | Cholangiocarcinoma | Research

A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept

Authors: Nora Nevermann, Julia Bode, Maxine Vischer, Lina Feldbrügge, Sebastian Knitter, Felix Krenzien, Uwe Pelzer, Uli Fehrenbach, Timo Alexander Auer, Georg Lurje, Moritz Schmelzle, Johann Pratschke, Wenzel Schöning

Published in: Langenbeck's Archives of Surgery | Issue 1/2023

Login to get access

Abstract

Purpose

The present study assesses long-term overall survival (OS) and disease-free survival (DFS) after curative resection for intrahepatic cholangiocarcinoma (ICCA) depending on resection margin (RM) status and lymph node (LN) status.

Methods

Clinical data of all consecutively resected patients with ICCA at a single high-volume center between 2005 and 2018 were collected. Minimum follow-up was 36 months. Perioperative and long-term oncological outcome was assessed.

Results

One hundred ninety-two cases were included in the analysis. Thirty- and 90-day-mortality was 5.2% (n = 10) and 10.9% (n = 21). OS was 26 months with 1-, 2-, and 5-year-OS rates of 72%, 53%, and 26%. One-, 2-, and 5-year-DFS rates were 54%, 42%, and 35% (N0 vs. N1: 29 vs. 9 months, p = 0.116). R1 was not found to be an independent risk factor for reduced survival in the overall cohort (p = 0.098). When differentiating according to the LN status, clear resection margins were significantly associated with increased DFS for N0 cases (50 months vs. 9 months, p = 0.004). For N1 cases, no significant difference in DFS was calculated for R0 compared to R1 cases (9 months vs. 9 months, p = 0.88). For N0 cases, clear resection margins > 10 mm were associated with prolonged OS (p = 0.048).

Conclusion

For N1 cases, there was no significant survival benefit when comparing R0 versus R1, while the complication rate remained high for the extended resection types. In view of merging multimodal treatment, the hilar first concept assesses locoregional LN status for optimal surgical therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Krenzien F, Nevermann N, Krombholz A, et al (2022) Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach. Cancers (Basel) 14(2) Krenzien F, Nevermann N, Krombholz A, et al (2022) Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach. Cancers (Basel) 14(2)
3.
go back to reference Murakami Y, Uemura K, Sudo T et al (2011) Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 18(3):651–658PubMedCrossRef Murakami Y, Uemura K, Sudo T et al (2011) Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 18(3):651–658PubMedCrossRef
4.
go back to reference Ribero D, Pinna AD, Guglielmi A et al (2012) Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg 147(12):1107–1113PubMedCrossRef Ribero D, Pinna AD, Guglielmi A et al (2012) Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg 147(12):1107–1113PubMedCrossRef
5.
go back to reference Spolverato G, Yakoob MY, Kim Y et al (2015) The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol 22(12):4020–4028PubMedCrossRef Spolverato G, Yakoob MY, Kim Y et al (2015) The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol 22(12):4020–4028PubMedCrossRef
6.
go back to reference Farges O, Fuks D, Boleslawski E et al (2011) Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg 254(5):824–829 discussion 830PubMedCrossRef Farges O, Fuks D, Boleslawski E et al (2011) Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg 254(5):824–829 discussion 830PubMedCrossRef
7.
go back to reference Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T (2008) Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 15(10):2787–2794PubMedCrossRef Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T (2008) Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 15(10):2787–2794PubMedCrossRef
8.
go back to reference Watanabe Y, Matsuyama Y, Izumi N et al (2020) Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: a nationwide survey of the Liver Cancer Study Group of Japan. Surgery 167(5):793–802PubMedCrossRef Watanabe Y, Matsuyama Y, Izumi N et al (2020) Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: a nationwide survey of the Liver Cancer Study Group of Japan. Surgery 167(5):793–802PubMedCrossRef
9.
go back to reference Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149(6):565–574PubMedCrossRef Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149(6):565–574PubMedCrossRef
10.
go back to reference Benzing C, Krenzien F, Mieg A et al (2021) A tailored approach in lymph node-positive perihilar cholangiocarcinoma. Langenbecks Arch Surg 406(5):1499–1509PubMedPubMedCentralCrossRef Benzing C, Krenzien F, Mieg A et al (2021) A tailored approach in lymph node-positive perihilar cholangiocarcinoma. Langenbecks Arch Surg 406(5):1499–1509PubMedPubMedCentralCrossRef
11.
go back to reference Bagante F, Spolverato G, Weiss M et al (2017) Impact of morphological status on long-term outcome among patients undergoing liver surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol 24(9):2491–2501PubMedCrossRef Bagante F, Spolverato G, Weiss M et al (2017) Impact of morphological status on long-term outcome among patients undergoing liver surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol 24(9):2491–2501PubMedCrossRef
12.
go back to reference Knitter S, Andreou A, Kradolfer D et al (2020) Minimal-invasive versus open hepatectomy for colorectal liver metastases: bicentric analysis of postoperative outcomes and long-term survival using propensity score matching analysis. J Clin Med 9(12):4027PubMedPubMedCentralCrossRef Knitter S, Andreou A, Kradolfer D et al (2020) Minimal-invasive versus open hepatectomy for colorectal liver metastases: bicentric analysis of postoperative outcomes and long-term survival using propensity score matching analysis. J Clin Med 9(12):4027PubMedPubMedCentralCrossRef
13.
go back to reference Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663–673PubMedCrossRef Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663–673PubMedCrossRef
14.
go back to reference Primrose JN, Fox R, Palmer DH et al (2017) Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol 35(15_suppl):4006–4006CrossRef Primrose JN, Fox R, Palmer DH et al (2017) Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol 35(15_suppl):4006–4006CrossRef
15.
go back to reference Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37(8):658–667PubMedCrossRef Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 37(8):658–667PubMedCrossRef
16.
go back to reference Park S, Sun JM, Choi YL et al (2022) Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. ESMO Open 7(1):100385PubMedPubMedCentralCrossRef Park S, Sun JM, Choi YL et al (2022) Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. ESMO Open 7(1):100385PubMedPubMedCentralCrossRef
17.
go back to reference de Jong MC, Nathan H, Sotiropoulos GC et al (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29(23):3140–3145PubMedCrossRef de Jong MC, Nathan H, Sotiropoulos GC et al (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29(23):3140–3145PubMedCrossRef
18.
go back to reference Bartsch F, Hahn F, Muller L et al (2020) Relevance of suspicious lymph nodes in preoperative imaging for resectability, recurrence and survival of intrahepatic cholangiocarcinoma. BMC Surg 20(1):75PubMedPubMedCentralCrossRef Bartsch F, Hahn F, Muller L et al (2020) Relevance of suspicious lymph nodes in preoperative imaging for resectability, recurrence and survival of intrahepatic cholangiocarcinoma. BMC Surg 20(1):75PubMedPubMedCentralCrossRef
19.
go back to reference Merath K, Chen Q, Bagante F et al (2019) A multi-institutional international analysis of textbook outcomes among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma. JAMA Surg 154(6):e190571PubMedPubMedCentralCrossRef Merath K, Chen Q, Bagante F et al (2019) A multi-institutional international analysis of textbook outcomes among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma. JAMA Surg 154(6):e190571PubMedPubMedCentralCrossRef
20.
go back to reference Subbiah V, Iannotti NO, Gutierrez M et al (2022) FIGHT-101, a first-in-human study of potent and selective FGFR 1–3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol 33(5):522–533PubMedCrossRef Subbiah V, Iannotti NO, Gutierrez M et al (2022) FIGHT-101, a first-in-human study of potent and selective FGFR 1–3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol 33(5):522–533PubMedCrossRef
21.
go back to reference Abou-Alfa GK, Macarulla T, Javle MM et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(6):796–807PubMedPubMedCentralCrossRef Abou-Alfa GK, Macarulla T, Javle MM et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(6):796–807PubMedPubMedCentralCrossRef
22.
go back to reference Valle JW, Borbath I, Khan SA et al (2016) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v28–v37PubMedCrossRef Valle JW, Borbath I, Khan SA et al (2016) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v28–v37PubMedCrossRef
23.
go back to reference Sahara K, Tsilimigras DI, Merath K et al (2019) Therapeutic index associated with lymphadenectomy among patients with intrahepatic cholangiocarcinoma: which patients benefit the most from nodal evaluation? Ann Surg Oncol 26(9):2959–2968PubMedCrossRef Sahara K, Tsilimigras DI, Merath K et al (2019) Therapeutic index associated with lymphadenectomy among patients with intrahepatic cholangiocarcinoma: which patients benefit the most from nodal evaluation? Ann Surg Oncol 26(9):2959–2968PubMedCrossRef
24.
go back to reference Kang CM, Suh KS, Yi NJ et al (2021) Should lymph nodes be retrieved in patients with intrahepatic cholangiocarcinoma? A collaborative Korea-Japan study. Cancers (Basel) 13(3):445PubMedCrossRef Kang CM, Suh KS, Yi NJ et al (2021) Should lymph nodes be retrieved in patients with intrahepatic cholangiocarcinoma? A collaborative Korea-Japan study. Cancers (Basel) 13(3):445PubMedCrossRef
25.
go back to reference Bartsch F, Baumgart J, Hoppe-Lotichius M, Straub BK, Heinrich S, Lang H (2020) Intrahepatic cholangiocarcinoma - influence of resection margin and tumor distance to the liver capsule on survival. BMC Surg 20(1):61PubMedPubMedCentralCrossRef Bartsch F, Baumgart J, Hoppe-Lotichius M, Straub BK, Heinrich S, Lang H (2020) Intrahepatic cholangiocarcinoma - influence of resection margin and tumor distance to the liver capsule on survival. BMC Surg 20(1):61PubMedPubMedCentralCrossRef
Metadata
Title
A surgical strategy for intrahepatic cholangiocarcinoma — the hilar first concept
Authors
Nora Nevermann
Julia Bode
Maxine Vischer
Lina Feldbrügge
Sebastian Knitter
Felix Krenzien
Uwe Pelzer
Uli Fehrenbach
Timo Alexander Auer
Georg Lurje
Moritz Schmelzle
Johann Pratschke
Wenzel Schöning
Publication date
01-12-2023
Publisher
Springer Berlin Heidelberg
Published in
Langenbeck's Archives of Surgery / Issue 1/2023
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-023-03023-y

Other articles of this Issue 1/2023

Langenbeck's Archives of Surgery 1/2023 Go to the issue